9α-(2,2-difluorovinyl)-estra-1,3,5(10)-triene-3,16α-diol | 634910-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 9α-(2,2-difluorovinyl)-estra-1,3,5(10)-triene-3,16α-diol
• 英文别名: 9alpha-(2,2-Difluorovinyl)-estra-1,3,5(10)-triene-3,16alpha-diol；(8S,9S,13R,14S,16R)-9-(2,2-difluoroethenyl)-13-methyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthrene-3,16-diol
• CAS: 634910-55-7
• 化学式: C₂₀H₂₄F₂O₂
• 分子量: 334.406
• InChiKey: CSSWHZNHVVPMMB-NWUDTAHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,16α-dihydroxyestra-1,3,5(10)-triene-9-carbaldehyde 、 二氟甲基膦酸二乙酯 在 正丁基锂 、 氯化铵 作用下， 以 乙二醇二甲醚 、 正戊烷 为溶剂， 反应 0.5h， 以21%的产率得到9α-(2,2-difluorovinyl)-estra-1,3,5(10)-triene-3,16α-diol
  参考文献：
  名称：

  [DE] 9-ALPHA-SUBSTITUIERTE ESTRATRIENE ALS SELEKTIV WIRKSAME ESTROGENE
  [EN] 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN
  [FR] ESTRATRIENES 9-ALPHA SUBSTITUES SERVANT D'OESTROGENES SELECTIVEMENT ACTIFS

  摘要：

  公开号：

  WO2003104253A3

文献信息

• 9-alpha-substituted estratrienes as selectively active estrogens
  申请人：Schering AG

  公开号：US20040087565A1

  公开（公告）日：2004-05-06

  This invention describes the new 9&agr;-substituted estratrienes of general formula I 1 in which R 3 , R 7 , R 7′ , R 13 , R 16 as well as R 17 and R 17′ have the meanings that are indicated in the description and R 9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.

  本发明描述了新的9&agr;-取代的雌三烯类化合物，其一般式为I1，其中R3、R7、R7'、R13、R16以及R17和R17'的含义如说明书中所示，R9表示直链或支链、可选择部分或完全卤代的烯基基团，其碳数为2到6，乙炔基或丙-1-炔基，作为药物活性成分。这些化合物在体外表现出比大鼠子宫雌激素受体制备更高的亲和力，并且在体内与子宫相比更倾向于对卵巢产生作用。本发明还描述了这些化合物的制备、治疗用途以及含有这些新化合物的药物剂型。本发明还描述了使用这些化合物治疗由雌激素缺乏引起的疾病和症状的方法。
• SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS
  申请人：KOSEMUND Dirk

  公开号：US20080132476A1

  公开（公告）日：2008-06-05

  This invention describes the new 9α-substituted estratrienes of general formula I in which R 3 , R 7 , R 7′ , R 13 , R 16 as well as R 17 and R 17′ have the meanings that are indicated in the description and R 9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop- 1 -inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.

  该发明描述了通式I的新型9α-取代的雌三烯类化合物，其中R3、R7、R7'、R13、R16以及R17和R17'的含义如说明书所示，R9表示直链或支链、可选部分或完全卤代的烯基基团，其具有2至6个碳原子、乙炔基或丙-1-烯基，作为药物活性成分，它们在体外对来自大鼠前列腺的雌激素受体制备表现出比对来自大鼠子宫的雌激素受体制备更高的亲和力，在体内优先作用于卵巢而非子宫，还描述了它们的制备、治疗用途以及含有这些新化合物的制药处方形式。该发明还描述了利用这些化合物治疗雌激素缺乏引起的疾病和病状的用途。
• 9-α-substituted estratrienes as selectively active estrogens
  申请人：Schering AG

  公开号：US07414043B2

  公开（公告）日：2008-08-19

  This invention describes the new 9α-substituted estratrienes of general formula I in which R3, R7, R7′, R13, R16 as well as R17 and R17′ have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.

  本发明描述了新的9α-取代的雌三烯酮通式I，其中R3、R7、R7′、R13、R16以及R17和R17′具有说明书中指定的含义，R9表示直链或支链、可选部分或完全卤代的烯基基团，其具有2至6个碳原子，乙炔基或丙-1-炔基，作为药物活性成分，其在体外表现出对来自大鼠前列腺的雌激素受体制备的亲和力高于对来自大鼠子宫的雌激素受体制备的亲和力，并在体内优先作用于卵巢而非子宫，其生产、治疗使用和含有新化合物的制药分配形式。本发明还描述了这些化合物用于治疗雌激素缺乏引起的疾病和病状的用途。
• 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2143432A1

  公开（公告）日：2010-01-13

  Use of 9α-estra-1,3,5(10)-triene derivatives of formula (I) for the prevention and treatment of intestinal cancer, in particular adenoma and adenocarcinoma of the duodenum, ileum, colon, and rectum.

  式（I）的 9α-雌甾-1,3,5(10)-三烯衍生物的用途 用于预防和治疗肠癌，特别是十二指肠、回肠、结肠和直肠的腺瘤和腺癌。
• 9-ALPHA-SUBSTITUIERTE ESTRATRIENE ALS SELEKTIV WIRKSAME ESTROGENE
  申请人：Schering Aktiengesellschaft

  公开号：EP1517914A2

  公开（公告）日：2005-03-30